42results about How to "Reduce drug dose" patented technology

The present invention provides a composition containing fine particles of a hardly-soluble drug which is stable and is not affected by storage environment conditions, as well as a manufacturing method therefor. The present invention provides a fine particle-containing composition containing fine particles of the hardly-soluble drug, a surfactant and a cyclic oligosaccharide, wherein an average particle size of the fine particles is at least 50 nm but not more than 1000 nm. The present invention also provides a method for manufacturing a fine particle-containing composition, comprising (I) a mixing step in which the hardly-soluble drug, the surfactant and a poor solvent are mixed to obtain a liquid mixture, (II) a pulverization step in which the liquid mixture is pulverized with a wet disperser to obtain a dispersion of fine particles, (III) an addition step in which the cyclic oligosaccharide is added to the dispersion of fine particles, and (IV) a drying step in which the dispersion of fine particles containing the cyclic oligosaccharide is dried.

Described herein is a network biology approach useful for the identification of multiple therapeutic targets, which can be targeted simultaneously using an agent (or a plurality of agents) to modulate cellular phenotypes, or in combination with pharmaceutical compounds to improve drug sensitivity and/or reduce drug doses to maintain efficacy while minimizing side effects. The preferred approach disclosed herein relies on first identifying the mediators of a condition of interest, and second, selecting gene combinations that are in competing/parallel pathways as targets for combination therapy.

There is provided a method and associated kit for reducing the normal dosage of a pharmaceutical given to a patient for the treatment of a disorder without substantially reducing its effectiveness. During a first predetermined time period, a substantially full dosage of the pharmaceutical is administered to the patient, preferably with a placebo. During a second predetermined time period, a reduced dosage of the pharmaceutical is administered to the patient, also with a placebo. The second predetermined time period is subsequent to the first predetermined time period. Preferably, the placebo has a distinctive indicia. The placebo, in association with the decreased pharmaceutical, augments the effectiveness of the pharmaceutical by heightening the patient's conditioned response and expectation of effectiveness.

Compositions comprising a polymer-based macroscopically homogeneous polymer alloy comprising a plurality of microcrystalline components dispersed within an amorphous component, which is biocompatible, bioerodable, substantially non-toxic, and excretable, or metabolized when introduced into a mammalian body. In preferred embodiments, malleable molded devices such as implants, films, drug delivery systems and the like, are comprised of the compositions. Methods of making such compositions by controlled cooling of the molten alloy are also described.

An oral celecoxib formulation, the formulation being a multiple minibead formulation wherein the minibeads comprise a hydrogel-forming polymer matrix in which are distributed celecoxib, a polyoxyethylated non-ionic surfactant and an anionic surfactant, the minibeads when combined with water being capable of releasing self-assembly structures comprising surfactant and celecoxib.

The formulation may be used for treating colorectal cancer, e.g. for inhibiting, reducing or delaying the initiation and/or progression of colorectal cancer, or for use in reversing colorectal cancer, reducing the burden of colorectal cancer and/or inducing remission of colorectal cancer, or for inhibiting, reducing or delaying metastasis of a colorectal cancer.

A method and system for leading macromolecule substances into target cells includes an image picking unit, an image merging unit, an injection unit, and an energy conversion module. The image picking unit is used for picking up the three-dimensional (3D) and the 3D blood vessel photographic images of the tissue or organ where the target cells locate. The image merging unit is used for merging the 3D structure images into the 3D blood vessel photographic images, therefore choosing a blood vessel passage fully covering the target cells for transmitting the macromolecule substances. The injection unit is used for injecting liquid and transmitting the macromolecule substances to the target cells. The energy conversion module is used for exerting energy to activate the liquid to perform biological effects, thereby forming non-permanent holes in the cell membranes of the target cells. The macromolecule substances enter into the target cells through the non-permanent holes.

The invention belongs to the technical field of pharmaceutical chemistry and particularly relates to medical use of 7-hydroxy-butylphthalide in preparation of drugs for preventing and/or treating cardiac and cerebral vascular diseases.

Disclosed is a transdermal preparation, comprising sequentially-stacked layers of a backing layer, a barrier layer, a drug adhesive layer and a release layer, wherein the drug adhesive layer contains a drug selected from the group consisting of fentanyl, an analogue thereof and a pharmaceutically-acceptable salt thereof, a skin permeation enhancer of the drug, and a polyacrylate adhesive, which shows a high skin permeation with a low drug dosage, equivalent to one with high drug dosage, by increasing the skin permeation rate of drug.

The invention discloses a blocked balloon dilation catheter. The front end of the balloon dilation catheter is a working area, the rear end of the working area is provided with a first blocking balloon, and the front end of the working area is provided with a second blocking balloon. Balloons, a drug administration micropore is arranged between the two blocking balloons, and the drug administration micropore is close to one of the blocking balloons; a working ball is arranged between the drug administration micropore and the balloon far away from the drug administration micropore A balloon, the effective length of the working balloon is greater than half of the distance between the drug delivery microhole and the balloon away from the drug delivery microhole. The blocked balloon dilation catheter of the present invention arranges a working balloon between the two balloons at the front end of the balloon dilation catheter, and squeezes the closed space between the two balloons into a thin-walled annular columnar shape, reducing At the same time, before removing the blocking, the pressure of the working balloon is released, and the diluent is added to dilute the liquid medicine, so as to avoid the damage of the high-concentration liquid medicine to the organs.

The phosphatide granule with subsidiary function of reducing blood fat consists of lecithin 16-60 wt%, tea polyphenol 1.0-2.5 wt%, ginkgo extract with 24 % over total flavone glycoside 0.39-1.5 wt%, vitamin C 1-5 wt%, vitamin E 0.16-1.5 wt%, vitamin B1 0.02-0.2 wt%, vitamin B2 0.02-0.2 wt% and starch 29.1-91.41 wt%. The present invention has several health functions, including emulsifying blood fat, preventing oxidation, accelerating fat metabolism and eliminating fat toxin, and thus can lower blood fat, raise body's immunity and strengthen physique.

Devices that are placed within fluid filled organs, such as the bladder, which reduce the risk of bacterial infections using a combination of active agents and mechanical disruption of bacteria.

Macrolide derivatives having enhancing effect for activities of azole antifungal agents, acting at low concentration and within a short time against fungal infection and reducing the frequency of appearance of resistant microorganisms. One such substance is a compound represented by the formula [I]:

wherein R1 is Ac, R2 and R3 are Ac, and R4 is Me; when R1 is H, R2 and R3 are Ac, and R4 is Me; when R1 is H, R2 and R3 are Ac, and R4 is H, when R1 Bzl, R2 and R3 are Bzl, and R4 is Me; when R1 is Ac, R2 and R3 are Pr, and R4 is Me; when R1 is Ac, R2 and R3 are Hex, and R4 is Me; when R1 is Ac, R2 and R3 are Bzl, and R4 is Me; when R1 is H, R2 and R3 are Pr, and R4 is Me; when R1 is H, R2 and R3 are Hex, and R4 is Me; when R1 is H, R2 and R3 are Bzl, and R4 is Me; when R1 is H, R2 is H, R3 is Bzl, and R4 is Me; when R1 is H, R2 and R3 are Hex, and R4 is H, or when R1 is H, R2 and R3 are Hex, and R4 is Et.

The invention discloses an external use type traditional Chinese medicine composition, and an extract, preparation and application thereof. The external use type traditional Chinese medicine composition is prepared from, by weight, 3-30 parts of semen cuscutae, 1.5-15 parts of fructus psoraleae, 3-30 parts of folium artemisiae argyi, 0.5-5 parts of cortex cinnamomi and 1-10 parts of rhizoma chuanxiong. The composition can treat both symptoms and root causes through acupoint application and transdermal absorption, stomachache caused by cold in uterus can be treated comprehensively, cold in uterus is relieved fundamentally, and therefore stomachache caused by cold in uterus is improved. The external use type traditional Chinese medicine composition can also be combined with mild moxibustion for indirect moxibustion treatment, so that fast relief and treatment of stomachache can be achieved, using is convenient, gastrointestinal tract side effects of drugs are avoided, and influences on hepatic and renal functions are reduced.